Akash Tewari
Stock Analyst at Jefferies
(1.65)
# 3,314
Out of 4,960 analysts
57
Total ratings
35.71%
Success rate
-1%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $7.32 | +36.61% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $47.92 | +41.90% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $58.58 | +62.17% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $110.88 | +35.28% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $3.69 | +333.60% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $135.43 | +39.56% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $27.97 | +186.02% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $42.69 | +75.69% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $994 → $1,015 | $711.68 | +42.62% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $29.75 | +68.07% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $38.27 | +95.98% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $17.38 | +78.37% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $589.48 | +58.95% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $25.88 | +50.70% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $8.83 | +103.85% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $660.00 | -22.27% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.93 | +159.74% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $87.37 | +43.07% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $15.10 | -27.15% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.36 | +1,150.00% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $38.34 | +95.62% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $414.68 | -63.59% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $38.63 | -27.52% | 3 | Oct 7, 2021 |
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $7.32
Upside: +36.61%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $47.92
Upside: +41.90%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $58.58
Upside: +62.17%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $110.88
Upside: +35.28%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $3.69
Upside: +333.60%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $135.43
Upside: +39.56%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $27.97
Upside: +186.02%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $42.69
Upside: +75.69%
Eli Lilly and Company
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $711.68
Upside: +42.62%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $29.75
Upside: +68.07%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $38.27
Upside: +95.98%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $17.38
Upside: +78.37%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $589.48
Upside: +58.95%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $25.88
Upside: +50.70%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $8.83
Upside: +103.85%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $660.00
Upside: -22.27%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $6.93
Upside: +159.74%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $87.37
Upside: +43.07%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $15.10
Upside: -27.15%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.36
Upside: +1,150.00%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $38.34
Upside: +95.62%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $414.68
Upside: -63.59%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $38.63
Upside: -27.52%